Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ROOPA INDUSTRIES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ROOPA INDUSTRIES Mar-23 |
ADCOCK INGRAM Jun-14 |
ROOPA INDUSTRIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 93 | 319 | - | |
Low | Rs | 24 | 230 | - | |
Sales per share (Unadj.) | Rs | 96.8 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 1.7 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 2.8 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 17.7 | 74.5 | - | |
Shares outstanding (eoy) | m | 7.87 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.6 | 2.9 | 20.8% | |
Avg P/E ratio | x | 34.0 | -11.5 | -295.9% | |
P/CF ratio (eoy) | x | 20.5 | -13.9 | -147.7% | |
Price / Book Value ratio | x | 3.3 | 3.7 | 89.2% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 459 | 46,340 | 1.0% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 32 | 2,908 | 1.1% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 762 | 16,016 | 4.8% | |
Other income | Rs m | 7 | 112 | 5.8% | |
Total revenues | Rs m | 768 | 16,128 | 4.8% | |
Gross profit | Rs m | 39 | -2,775 | -1.4% | |
Depreciation | Rs m | 9 | 691 | 1.3% | |
Interest | Rs m | 18 | 434 | 4.3% | |
Profit before tax | Rs m | 18 | -3,788 | -0.5% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 5 | 237 | 1.9% | |
Profit after tax | Rs m | 13 | -4,036 | -0.3% | |
Gross profit margin | % | 5.1 | -17.3 | -29.5% | |
Effective tax rate | % | 25.3 | -6.2 | -405.0% | |
Net profit margin | % | 1.8 | -25.2 | -7.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 421 | 11,730 | 3.6% | |
Current liabilities | Rs m | 396 | 6,600 | 6.0% | |
Net working cap to sales | % | 3.3 | 32.0 | 10.3% | |
Current ratio | x | 1.1 | 1.8 | 59.8% | |
Inventory Days | Days | 17 | 111 | 15.5% | |
Debtors Days | Days | 339 | 124 | 273.6% | |
Net fixed assets | Rs m | 145 | 6,838 | 2.1% | |
Share capital | Rs m | 79 | 74 | 105.8% | |
Net worth | Rs m | 139 | 12,571 | 1.1% | |
Long term debt | Rs m | 17 | 4,418 | 0.4% | |
Total assets | Rs m | 565 | 23,747 | 2.4% | |
Interest coverage | x | 2.0 | -7.7 | -25.6% | |
Debt to equity ratio | x | 0.1 | 0.4 | 34.2% | |
Sales to assets ratio | x | 1.3 | 0.7 | 199.7% | |
Return on assets | % | 5.6 | -15.2 | -37.2% | |
Return on equity | % | 9.7 | -32.1 | -30.1% | |
Return on capital | % | 23.4 | -19.8 | -118.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 89 | 1,367 | 6.5% | |
From Investments | Rs m | -10 | -420 | 2.4% | |
From Financial Activity | Rs m | -75 | 4,009 | -1.9% | |
Net Cashflow | Rs m | 5 | 4,957 | 0.1% |
Compare ROOPA INDUSTRIES With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare ROOPA INDUSTRIES With: KERALA AYURV FERMENTA BIOTECH AAREY DRUGS GRANULES INDIA MOREPEN LABS
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.